Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Secoisolariciresinol is a plant lignan found primarily in flaxseeds that converts to enterolignans in the gut microbiome. It reduces cholesterol through HMG-CoA reductase inhibition and may lower breast cancer risk by modulating estrogen metabolism.
Origin & History
Secoisolariciresinol diglucoside (SDG) is a plant lignan primarily found in flaxseed (Linum usitatissimum), where it exists as the main lignan component bound to glucose molecules. It is extracted from defatted flaxseed meal using methods like alkaline hydrolysis or microwave-assisted germination, followed by purification to concentrate the lignans.
Research Narrative (Provisional)
Two key human RCTs have evaluated SDG: a 2024 trial (PMC11111469) with 74 participants showing LDL cholesterol reduction in men at 60mg/day, and a 2020 Phase IIB trial (PMID: 32312713) with 180 premenopausal women showing modest Ki-67 reduction at 50mg/day. No meta-analyses were identified, and other studies remain preclinical.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Secoisolariciresinol (SDG) is a pure lignan compound, not a whole food, so traditional macronutrient/micronutrient profiling does not apply. As an isolated phytochemical compound: Molecular weight: 362.46 g/mol. Chemical class: Plant lignan (dibenzylbutanediol). Not a source of calories, protein, fat, fiber, vitamins, or minerals in supplemental form. Bioactive compound concentration in common dietary sources: flaxseed is the richest known source at 75–800 mg SDG per 100g dry weight (varies by variety and processing); sesame seeds contain ~29–37 mg/100g; sunflower seeds ~0.6 mg/100g; rye bread ~0.07–0.09 mg/100g. In supplement form, standardized flaxseed lignans typically deliver 50–600 mg SDG per dose. Bioavailability notes: SDG is not absorbed intact; gut microbiota convert SDG to enterolignans enterodiol (ED) and enterolactone (EL), which are the primary circulating bioactive forms. Conversion efficiency varies significantly based on gut microbiome composition, antibiotic use, and diet. Peak plasma enterolignans reached approximately 8–10 hours post-ingestion. Fat co-ingestion may modestly improve absorption. Enterolactone plasma concentrations after 60 mg/day SDG supplementation in RCT conditions reached approximately 20–40 nmol/L. SDG also exhibits weak phytoestrogenic activity via its enterolignan metabolites, with affinity for estrogen receptor beta (ERβ) >> ERα.
Reported Mechanism (Provisional)
Secoisolariciresinol diglucoside (SDG) is converted by gut bacteria into enterolignans enterodiol and enterolactone, which act as selective estrogen receptor modulators (SERMs). These metabolites inhibit HMG-CoA reductase, reducing cholesterol synthesis, and compete with endogenous estrogens at estrogen receptors. The compound also modulates aromatase activity and enhances sex hormone-binding globulin production.
Clinical Narrative (Provisional)
A 2024 randomized controlled trial demonstrated that 60mg daily secoisolariciresinol significantly reduced LDL cholesterol and total cholesterol in men over 12 weeks, representing moderate-quality evidence. A Phase IIB randomized trial found SDG reduced Ki-67 proliferation markers by 2.2% in premenopausal women at high breast cancer risk. However, evidence remains limited with small sample sizes and short-term follow-up periods. More large-scale, long-term studies are needed to confirm therapeutic efficacy.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.